Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Ciltacabtagene autoleucel in Multiple Myeloma: NCT07149857 Clinical Landscape Report 2026
15 October 2026
NCT07149857 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
supCD7 CART(Institute of Hematology & Blood Diseases Hospital) in Acute Myeloid Leukemia: NCT07153068 Clinical Landscape Report 2026
15 October 2026
NCT07153068 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HSK-44459 in Plaque psoriasis: NCT07150988 Clinical Landscape Report 2026
15 October 2026
NCT07150988 clinical landscape for Plaque psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT07148180 Clinical Landscape Report 2026
15 October 2026
NCT07148180 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RSS0393 in Dermatitis, Atopic: NCT07158151 Clinical Landscape Report 2026
15 October 2026
NCT07158151 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BG-2205 in Connective Tissue Diseases: NCT07152223 Clinical Landscape Report 2026
15 October 2026
NCT07152223 clinical landscape for Connective Tissue Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in HER2 Positive Muscle Invasive Bladder Carcinoma: NCT07151560 Clinical Landscape Report 2026
15 October 2026
NCT07151560 clinical landscape for HER2 Positive Muscle Invasive Bladder Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develop…
9 min read
Fludarabine Phosphate in Scleroderma, Systemic: NCT07155369 Clinical Landscape Report 2026
15 October 2026
NCT07155369 clinical landscape for Scleroderma, Systemic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Posaconazole in Acute Myeloid Leukemia: NCT07155226 Clinical Landscape Report 2026
15 October 2026
NCT07155226 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(Beijing Minhai Biological Technology Co., Ltd.) in Multiple Myeloma: NCT07154537 Clinical Landscape Report 2026
15 October 2026
NCT07154537 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Decitabine/Cedazuridine in IDH1 Mutation Acute Myeloid Leukemia: NCT07153497 Clinical Landscape Report 2026
15 October 2026
NCT07153497 clinical landscape for IDH1 Mutation Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Fludarabine Phosphate in Relapsing acute myeloid leukemia: NCT07157514 Clinical Landscape Report 2026
15 October 2026
NCT07157514 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…